STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2023

STOCKHOLDERS' EQUITY [Abstract]

Schedule of Assumptions

The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2023 and 2022:

	Six Months Ended June 30,
	2023			2022
Expected term	5.5 - 6.3 years			5.5 - 6.3 years
Volatility		68	%		68	%
Dividend yield		0.0			0.0
Risk-free interest rate		4.20-4.24	%		1.72-1.73	%

Schedule of Option Activity

A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2022		8,256,211		$	3.37
Forfeited		(76,866	)	$	2.86
Expired		(81,298	)	$	5.72
Granted		1,727,510		$	3.35
Exercised		(184,245	)	$	2.62
Options outstanding, vested and expected to vest at June 30, 2023		9,641,312		$	3.36
Options exercisable		6,690,912		$	3.64

Schedule of Unvested RSU Activity

A summary of the Company’s unvested RSU activity and related information is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2022		2,866,987		$	1.59
Granted		2,976,260		$	3.37
Vested		(806,781	)	$	1.64
Forfeited		(217,817	)	$	2.53
Balance at June 30, 2023		4,818,649		$	2.64

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and six months ended June 30, 2023 and 2022 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Research and development	$	9,418	$	4,898	$	14,803	$	9,569
Plasma center operating expenses		39,707		19,615		62,762		40,667
Selling, general and administrative		1,410,073		1,068,215		2,388,197		2,585,817
Cost of product revenue		177,840		98,319		281,442		196,382
Total stock-based compensation expense	$	1,637,038	$	1,191,047	$	2,747,204	$	2,832,435